- BIST10011,643-1.31%
- USD49.58+0.05%
- EUR55.62+0.09%
- GOLD4,155.60+0.31%
- INTEREST37.00%-1.00
- BITCOIN83,660+0.87%
- October 21, 202612°
- BIST10011,643-1.31%
- USD49.58+0.05%
- EUR55.62+0.09%
- GOLD4,155.60+0.31%
- INTEREST37.00%-1.00
- BITCOIN83,660+0.87%
- October 21, 202612°
Could Ozempic and Wegovy Reduce Breast Cancer Recurrence Risk?
A Texas breast surgeon has stated that diabetes and obesity drugs Ozempic and Wegovy may be associated with a reduced risk of breast cancer recurrence. However, the expert emphasized that these findings are observational and it has not been proven that the drugs directly prevent cancer.
Texas-based breast surgeon Dr. Loren Rourke has indicated that GLP-1 drugs, widely used for diabetes and obesity, may also have a potential role in cancer prevention. She stated that glucagon-like peptide-1 (GLP-1) drugs such as Ozempic and Wegovy may be associated with a reduced risk of breast cancer recurrence.
Dr. Rourke highlighted research findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies found an association between GLP-1 drug use and lower breast cancer recurrence rates. However, Rourke noted that the evidence is only observational and it has not yet been proven that the drugs reduce cancer risk.
Weight Loss and Reduced Inflammation Play a Key Role
According to Dr. Rourke, the main reason GLP-1s may help prevent cancer is that they promote weight loss and reduce chronic inflammation. These drugs lead to weight loss by lowering body mass index (BMI). It is known that a lower BMI is associated with a better prognosis in breast cancer.
Women struggling with postmenopausal weight gain may see an additional benefit. Excess fat tissue increases estrogen production. Rourke said, "The more fat you have, the higher your estrogen production. Your body essentially bathes in estrogen. So it makes sense that we see this correlation or association."
GLP-1s also reduce the inflammatory state in which cancer develops. Rourke added, "Correcting chronic inflammation will help for many reasons."
More Research Needed for Definitive Results
Rourke emphasized that researchers have not yet proven that GLP-1 drugs directly affect breast cancer cells. "But this study has gathered enough attention, interest, and scientific hypothesis to start the randomized controlled trials we are all waiting for. Then we can act based on those results," she said.
Advising patients considering GLP-1 use, Rourke said, "If your BMI is high, you're trying to lose weight, you've tried healthy diet and exercise but haven't succeeded, consider GLP-1s. You'll get a secondary benefit." She added that women who gain weight after menopause may particularly benefit, but they should definitely consult their doctors.
Stay Updated with Ally Daily
Subscribe to be informed about special news, developments and announcements. We will keep you informed.
By signing up, you agree to our Privacy Policy
